ATTY. DOCKET NO. SERIAL NO. 10/076,204

CONFIRMAT

8595

FILING DATE GROUP February 13, 2002 1614

APPLICANT

Levi, et al.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

MAY 17 2002 8

FOREIGN PATENT DOCUMENTS

		ICCIOITI	TENT BEECH		i i	·	
EXAMINER INITIAL	DOCUMENT	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
	NUMBER					YES	NO
Ne	WO/00/20011	4/13/00	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	OTHER D	OCOMENTS (including Author, Title, Date, Fertinent Fages, Etc.)
A	1.	B Malinowska, et al., "Histamine H <sub>3</sub> Receptors - General Characterization and Their Function in the Cardiovascular System", <i>Journal of Physiology and Pharmacology</i> , 1998. 49(2):191-211.
	2.	H. van der Goot, et al., "Isothiourea Analogues of Histamine as Potent Agonists or Antagonists of the Histamine H <sub>3</sub> -Receptor" <i>Eur. J. Med. Chem.</i> 1992. 27: 511-517.
	3.	Iwan J.P. De Esch, et al., "Characterization of the Binding Site of the Histamine H <sub>3</sub> Receptor. 1. Various Approaches to the Synthesis of 2-(1H-Imidazol-4-yl) cyclopropylamine and Histaminergic Activity of (1R,2R)- and (1S,2S)-2-(1H-Imidazol-4-yl)-cyclopropylamine", Journal of Medicinal Chemistry, 1999. 42(7): 1115-1122.
	4.	Christina J. Mackins, et al., "Therapeutic Potential of H <sub>3</sub> -receptor Agonists in Myocardial Infarction", Exp. Opin. Invest Drugs 2000. 9(11): 2537-2542.
	5.	Catherine Mazenot, et al., "Histamine H <sub>3</sub> -receptor Stimulation is Unable to Modulate Noradrenaline Release by the Isolated Rat Heart During Ischaemia-Reperfusion", Fundam. Clin. Pharmacol. 1999. 13(4): 455-60.
	6.	Catherine Mazenot, et al., "In vivo Demonstration of H <sub>3</sub> -histaminergic Inhibition of Cardiac Sympathetic Stimulation by R-α-methyl-histamine and its Prodrug BP 2.94 in the Dog", British Journal of Pharmacology 1999. 126: 264-268.
A	7.	Pierre Theroux, M.D., "Myocardial Cell Protection. A Challenging Time for Action and Challenging Time of Clinical Research", Circulation 2000. 101:2874-2876.

EXAMINER ZILLA DATE CONSIDERED 8/24/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE			ATTY. DOCKET NO. 955-16	SERIAL NO. 10/076,204
PE		TION DISCLOSURE INT BY APPLICANT	APPLICANT Levi, et al.	CONFIRMATION NO. 8595
1 7 2002 5	(Use severa	I sheets if necessary)	FILING DATE February 13, 2002	GROUP 1614
TRADENTIFE	8.	Hans-Jurgen Rupprecht, M.D., Exchange Inhibitor Cariporide infarction Undergoing Direct P	in Patients with Acute	Anterior Myocardial
MAY CENT	REC	Morris Karmazyn, et al., "The Negulation and Its Role in Hear 85:777-786.		
MAY 2 3 2002 EOH CENTER 1600/2900	10.	Eiichiro Hatta, et al., "Activation of Histamine H <sub>3</sub> Receptors Inhibits Carrier-Mediated Norepinephrine Release in a Human Model of Protracted Myocardial Ischemia", <i>Journal of Pharmacology and Experimental Therapeutics</i> 1997. 283:494-500.		
8	11.	Randi B. Silver, et al., "Couplin Na <sup>+</sup> /H <sup>+</sup> Exchange: A Protective <i>Early Edition</i> 2001. 1-5.		
	12.	Rob Leurs, et al., "Therapeutic and Antagonists", <i>Trends in Pha</i>		
	13.	P.K. Rangachari, "The Fate of I Termination", Yale Journal of E		
	14.	Randi B. Silver, et al., "Couplin Na <sup>+</sup> /H <sup>+</sup> Exchange: A Novel Pro <i>PNAS</i> 2001. 98(5):2855-2859.		
	15.	Michiaki Imamura, et al., "Activate Carrier-Mediated Norepinephring Ischemia", Circ. Res. 1996. 78:	ne Release During Pro	
	16.	Roberto Levi, et al., "Histamine Ischemia", The Journal of Phan		
		2000. 292:825-830.		

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

DATE CONSIDERED

EXAMINER

*		······································		
		PARTMENT OF COMMERCE D TRADEMARK OFFICE	ATTY. DOCKET NO. 955-16	SERIAL NO. 10/076,204
		TION DISCLOSURE NT BY APPLICANT	APPLICANT Levi, et al.	CONFIRMATION NO. 8595
N 1 7 2002 5	e several	sheets if necessary)	FILING DATE February 13, 2002	GROUP 1614
4 MADERNOT	18.	Cholinergic Systems in La	ole of Interactions Between earning and Memory", 98/huston/blandina0227/two	<u> </u>
RECEI MAY 201	19.	Rob Leurs, et al., "Histam www.biotrend.com/pdf/hi	nine Receptors", <i>Tocris Coo</i> stamine.pdf. 1-6.	kson. Late Augilable)
AY C				

EXAMINER 201/1/2

DATE CONSIDERED

5/24/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
St	1.	Akagi, et al., "Role of histamine H <sub>3</sub> receptor on hypoxia-reoxygenation-induced cardiac dysfunction in guinea pigs", PubMed No. 8750792, <i>Methods Find Exp. Clin. Pharmacol.</i> , 1995, Vol. 17 Suppl C:30-35. (abstract only).			
	2.	Imamura, Michiaki, et al., "Histamine H <sub>3</sub> -Receptor-Mediated Inhibition of Calcitonin Gene-Related Peptide Release From Cardiac C Fibers", Circulation Research 1996, 78(5):863-869.			
A	3.	Luo, Xiao-Xing, et al., "Histamine H <sub>3</sub> -receptors inhibit sympathetic neurotransmission in guinea pig myocardium", <i>European Journal of Pharmacology</i> 1991, 204:311-314.			

171032\_1

EXAMINER ZI / Jan DATE CONSIDERED 8/24/13

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.